To assess the single dose pharmacokinetics, safety, and tolerability of GLA5PR GLARS-NF3 tablet 150mg administered regular die relative to GLA5PR GLARS-NF1 tablet 150mg administered regular diet. IP will be administered 1 tablet(150mg) once a day(QD) after evening meal.